Literature DB >> 11825950

Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2.

Bodo Rolf Eing1, Lars Lippelt, Eva Ulla Lorentzen, Wali Hafezi, Wolfgang Schlumberger, Katja Steinhagen, Joachim Ewald Kühn.   

Abstract

In this study, the optimal combination of three commercial glycoprotein G-2 (gG-2)-based herpes simplex virus type 2 (HSV-2) type-specific enzyme-linked immunosorbent assays (Euroimmun anti-HSV-2 immunoglobulin G [IgG] ELISA [Eu2], Gull HSV-2-specific IgG ELISA [Gu2], and Radim HSV-2 IgG ELISA [Ra2]) and one gG-2-based HSV-2-specific immunoblot (Euroimmun anti-HSV-1/HSV-2 gG Western blot [EuW]) was determined with regard to diagnostic performance and cost efficiency. Two hundred fifty serum samples were included in this study, 194 of which were from female prostitutes. When a formal primary "gold standard" was defined based on majority agreement of the commercial tests, with EuW being decisive in stand-off situations, the sensitivity and specificity of the assays in the samples from prostitutes were as follows: Eu2, 100 and 89.22%; Gu2, 94.44 and 96.08%; Ra2, 61.18 and 95.10%; and EuW, 98.90 and 100%. The most cost-effective confirmatory strategy in the samples from prostitutes was screening with Eu2, retesting positive and equivocal samples with Gu2, and resolving the remaining discordant results with EuW (estimated additional costs per sample, 79.02%; sensitivity, 100%; positive predictive value, 96.81%). Applying a self-developed gG-2-independent assay to the discordant and concordant negative samples in the samples from prostitutes suggested that the primary gold standard may have missed six HSV-2-positive samples. In conclusion, confirmatory strategies based on commercial gG-2-dependent seroassays result in an increase in the specificity of HSV-2-specific serology. However, further improvement of the sensitivity of current HSV-2-specific serology may require the additional exploitation of the gG-2-independent type-specific antibody response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825950      PMCID: PMC153348          DOI: 10.1128/JCM.40.2.407-413.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Genital herpes and public health: addressing a global problem.

Authors:  L Corey; H H Handsfield
Journal:  JAMA       Date:  2000-02-09       Impact factor: 56.272

2.  Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type.

Authors:  W E Lafferty; R W Coombs; J Benedetti; C Critchlow; L Corey
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

3.  DNA sequence and genetic content of the HindIII l region in the short unique component of the herpes simplex virus type 2 genome: identification of the gene encoding glycoprotein G, and evolutionary comparisons.

Authors:  D J McGeoch; H W Moss; D McNab; M C Frame
Journal:  J Gen Virol       Date:  1987-01       Impact factor: 3.891

4.  A novel glycoprotein for detection of herpes simplex virus type 1-specific antibodies.

Authors:  F K Lee; L Pereira; C Griffin; E Reid; A Nahmias
Journal:  J Virol Methods       Date:  1986-09       Impact factor: 2.014

5.  Detection of herpes simplex virus type 2-specific antibody with glycoprotein G.

Authors:  F K Lee; R M Coleman; L Pereira; P D Bailey; M Tatsuno; A J Nahmias
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

Review 6.  Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world.

Authors:  A J Nahmias; F K Lee; S Beckman-Nahmias
Journal:  Scand J Infect Dis Suppl       Date:  1990

7.  Glycoprotein G of herpes simplex virus type 1: identification of type-specific epitopes by human antibodies.

Authors:  P Tunbäck; J A Liljeqvist; G B Löwhagen; T Bergström
Journal:  J Gen Virol       Date:  2000-04       Impact factor: 3.891

8.  HSV-1 gB and VZV gp-II crossreactive antibodies in human sera.

Authors:  J E Kühn; K Klaffke; K Munk; R W Braun
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

9.  The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections.

Authors:  D I Bernstein; M A Lovett; Y J Bryson
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

10.  Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera.

Authors:  R L Ashley; J Militoni; F Lee; A Nahmias; L Corey
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

View more
  6 in total

1.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Performance of two commercial enzyme-linked immunosorbent assay kits using recombinant glycoprotein G2 antigen for detection of herpes simplex virus type 2 specific antibodies.

Authors:  Sharmila M Reddy; P Balakrishnan; S Uma; S P Thyagarajan; Suniti Solomon
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 4.  HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa.

Authors:  Laith J Abu-Raddad; Joshua T Schiffer; Rhoda Ashley; Ghina Mumtaz; Ramzi A Alsallaq; Francisca Ayodeji Akala; Iris Semini; Gabriele Riedner; David Wilson
Journal:  Epidemics       Date:  2010-09-15       Impact factor: 4.396

5.  Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG.

Authors:  Fernando de Ory; María-Eulalia Guisasola; Pilar Balfagón; Juan Carlos Sanz
Journal:  J Clin Lab Anal       Date:  2017-03-23       Impact factor: 2.352

6.  Comparative performance of the Uni-Gold™ HSV-2 Rapid: a point-of-care HSV-2 diagnostic test in unselected sera from a reference laboratory.

Authors:  Enda Shevlin; Rhoda Ashley Morrow
Journal:  J Clin Virol       Date:  2014-08-27       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.